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ABSTRACT
Background
Previous studies of drug trials submitted to regulatory authorities have documented selective
reporting of both entire trials and favorable results. The objective of this study is to determine
the publication rate of efficacy trials submitted to the Food and Drug Administration (FDA) in
approved New Drug Applications (NDAs) and to compare the trial characteristics as reported by
the FDA with those reported in publications.
Methods and Findings
This is an observational study of all efficacy trials found in approved NDAs for New Molecular
Entities (NMEs) from 2001 to 2002 inclusive and all published clinical trials corresponding to the
trials within the NDAs. For each trial included in the NDA, we assessed its publication status,
primary outcome(s) reported and their statistical significance, and conclusions. Seventy-eight
percent (128/164) of efficacy trials contained in FDA reviews of NDAs were published. In a
multivariate model, trials with favorable primary outcomes (OR ¼ 4.7, 95% confidence interval
[CI] 1.33–17.1, p¼0.018) and active controls (OR¼3.4, 95% CI 1.02–11.2, p¼0.047) were more
likely to be published. Forty-one primary outcomes from the NDAs were omitted from the
papers. Papers included 155 outcomes that were in the NDAs, 15 additional outcomes that
favored the test drug, and two other neutral or unknown additional outcomes. Excluding
outcomes with unknown significance, there were 43 outcomes in the NDAs that did not favor
the NDA drug. Of these, 20 (47%) were not included in the papers. The statistical significance of
five of the remaining 23 outcomes (22%) changed between the NDA and the paper, with four
changing to favor the test drug in the paper (p ¼ 0.38). Excluding unknowns, 99 conclusions
were provided in both NDAs and papers, nine conclusions (9%) changed from the FDA review
of the NDA to the paper, and all nine did so to favor the test drug (100%, 95% CI 72%–100%, p
¼ 0.0039).
Conclusions
Many trials were still not published 5 y after FDA approval. Discrepancies between the trial
information reviewed by the FDA and information found in published trials tended to lead to
more favorable presentations of the NDA drugs in the publications. Thus, the information that
is readily available in the scientific literature to health care professionals is incomplete and
potentially biased.
The Editors’ Summary of this article follows the references.
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Evidence-based clinical medicine relies on the publication
of high-quality data to determine standards of patient care.
Publication bias occurs when some types of results (e.g., those
that are statistically signiﬁcant) are reported more frequently
or more quickly than others [1–4]. Publication bias favors the
dissemination of information about clinical interventions
showing statistically signiﬁcant beneﬁt. Publication bias,
therefore, may lead to preferential prescribing of newer
and more expensive treatment choices and may under-
estimate the harms of drugs that have been in use for only
a limited time, and clinical decisions may be based on
erroneous information [5]. The objective of this study is to
assess the extent and nature of publication bias among newly
approved drugs by determining the publication rate of
efﬁcacy trials submitted to the United States Food and Drug
Administration (FDA) in approved New Drug Applications
(NDAs) for NMEs (New Molecular Entities) and comparing
the trial characteristics as reported by the FDA with those
reported in publications.
Publication bias not only limits the number and scope of
studies available for review by clinicians, but also affects the
results of systematic reviews and meta-analyses. Researchers
may estimate spuriously large treatment effects in early meta-
analyses of the available evidence if there is publication bias
[4].
The fact that unpublished trials are hidden from view makes
it difﬁcult to study publication bias among drug trials [6–8].
However, drug manufacturers seeking approval to market
drugs in the US are required to submit all studies to the FDA
as part of their NDA. Thus, documents submitted to regulatory
agencies can be used to help identify unpublished trials. Past
studies found selective reporting of both entire trials and
favorable results [9–13]. One study conducted in the US
examined 37 trials of nonsteroidal anti-inﬂammatory drugs
that were submitted to the FDA and found that only one trial
was published [14]. However, because only one trial was
published, trial characteristics that might be associated with
publication could not be examined. Another US study
examined trials of antidepressants that were submitted to
the FDA and also found evidence of publication bias, although
this analysis was again limited to one drug category and
included drugs approved in a wide range of years (1987–2004),
during which time publication practices may have changed
substantially as journals began to require trial registration [12].
In this study, we hypothesized that not all data submitted to
the FDA for a new drug approval are published and that
certain trial characteristics may be associated with publica-
tion. We also hypothesized that there are discrepancies
between trial data submitted to the FDA and data found in
published trials. We compared the efﬁcacy trials submitted to
the FDA in approved NDAs with their publications, if any, in
the medical literature. For those trials that were published,
we compared characteristics of each trial as reported by the
FDA with characteristics as reported in the corresponding
publication.
Methods
We conducted a study of all efﬁcacy trials found in
approved NDAs for new molecular entities (NMEs) from
2001 to 2002 inclusive and all published clinical trials
corresponding to the trials within the NDAs. NMEs are a
subset of NDAs that represent novel active ingredients rather
than, for example, ‘‘me-too’’ drugs, which are very similar to
existing drugs, or combinations of previously approved drugs.
Thus, NMEs are clinically important drugs about which new
information is needed.
Search Strategy: New Drug Applications (NDAs)
We (KR and LB) ﬁrst identiﬁed all NDAs for NMEs
approved from January 2001 to December 2002. An NME,
as deﬁned by the FDA, is an active ingredient that has never
before been marketed in the US in any form [15]. We found
this information at the Center for Drug Evaluation and
Research website [16].
This 2-year period was selected in order to include trials
that were recently conducted, while still allowing enough time
for publication. Prior research found a median time to
publication of 5.5 y from the time a trial started enrollment,
with trials with positive results published signiﬁcantly earlier
than trials with negative results (4.3 y versus 6.5 y,
respectively) [4]. NDAs for drugs that were withdrawn from
the market were excluded, as withdrawal of the drug would
likely affect the subsequent publication of trials.
Information submitted in NDAs is contained in the FDA
Medical and Statistical Ofﬁcer Reviews of each NDA, which
are publicly available, along with approval letters, at http://
www.accessdata.fda.gov/scripts/cder/drugsatfda/index.
cfm?fuseaction¼Search.Search_Drug_Name.
Search Strategy: NDA Trials
The approval letter for each drug was read to determine
the indication(s) for which the drug was approved. The
medical and statistical ofﬁcer reviews were then reviewed to
identify all clinical trials referred to within efﬁcacy sections
of the reviews that met our inclusion criteria. We call these
trials that were submitted in support of efﬁcacy ‘‘efﬁcacy
trials.’’
Inclusion Criteria for Trials within the NDA
Each NDA submitted to the FDA contains one or more
efﬁcacy trials for each indication for which the drug is under
evaluation. We included in our study all trials that the FDA
ofﬁcers included in their efﬁcacy review of the NDA for the
approved indication(s) only.
Speciﬁc inclusion criteria for trials within the FDA reviews
were: had a comparison group (placebo or comparator drug);
included patients with the condition for which the NDA was
approved; were used by the FDA in the efﬁcacy review of the
drug; had separately reported results somewhere within the
medical or statistical review, unless a pooled analysis of two
or more trials was pre-speciﬁed; were reported with enough
information to be able to search for them within the
published literature (for example, some combination of
patient population description, intervention description,
sample size, outcomes measured, location of trial, etc.); and
had complete analysis at time of reporting, or analysis of the
primary outcome(s) was complete if the trials had long-term
extensions.
Search Strategy: Published Trials
We performed an electronic search of PubMed and The
Cochrane Library from July 2006 through June 2007,
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identify publications that corresponded to each of the trials
identiﬁed in the FDA reviews of each NDA. Trade and generic
names were used to search online databases, as well as any
other names, such as code names, that had been used in the
NDA text describing the trial. We searched for articles
published in any language. In addition, the reference lists of
identiﬁed articles were scanned for additional relevant
published trials and investigators and drug companies were
contacted multiple times to inquire about publication status.
If no publications were identiﬁed for a trial within a
speciﬁc NDA, authors of other publications identiﬁed for that
drug were contacted to request assistance identifying the
publications of the other trials. Trials were referred to as
protocol numbers when available from the NDA, and
otherwise by name or any other speciﬁc identifying informa-
tion (such as location of study, number of participants, or
intervention groups). If further assistance was required, the
drug company was contacted. If a publication was identiﬁed
that was thought to possibly be one of the included trials, but
the identity was not certain, the author of that publication
was contacted to inquire whether the publication was
reporting the trial of interest (identiﬁed by protocol number
if available). When contacting authors, the corresponding
author was contacted ﬁrst. If the author did not reply, a
second email was sent or a phone call was made if a phone
number was available. Attempts were also made to contact
any other authors of the publications for whom contact
information could be found. On average, about three
attempts were made to establish contact with someone
(author or drug company) regarding publication of each
trial. This process was followed with each publication
identiﬁed for each trial included in the study. Contact was
made only in instances in which trial identity was unclear in a
publication, or for which no publication had been found for a
trial.
Published trials were linked to trials found in the NDA by
comparing descriptions of methods and data on the
characteristics of the population studied, including sample
size, intervention groups, outcomes measured, and results of
the trial.
The publication status of each NDA trial was recorded as
(1) individual publication, (2) publication in press, (3) pooled
publication reported separately, (4) pooled publication not
reported separately, (5) abstract, (6) poster, (7) not published,
veriﬁed; or (8) no information found. A trial was considered
‘‘not published, veriﬁed’’ (category 7 above) only with
veriﬁcation from the drug company or an investigator
associated with that trial. Trials that were reported to be
‘‘in press’’ were considered published but were excluded from
all additional analysis, as the published reports could not be
reviewed.
For analysis, the coding categories above were dichotom-
ized as ‘‘published’’ or ‘‘not published’’. A trial was coded as
‘‘published’’ if it was in categories 1, 2 or 3 above; it was coded
as an individual publication if one or more publications were
identiﬁed reporting only the results of that speciﬁc trial; as in
press; or as a pooled publication if multiple trials were
included but the results of the NDA trial were reported
separately. All other trials (categories 4, 5, 6, 7 or 8 above)
were coded as ‘‘not published’’.
Data Extraction
We designed a database into which we directly entered all
information on publication status and trial characteristics.
The database was pre-tested on trials and papers that were
not included in our study, and unclear/unreliable data
extraction elements were eliminated or revised.
One author (KR) extracted all data from all NDA trials and
publications. A random number generator was used to
determine the order in which the drugs were reviewed. The
data from all trials, both in the NDA and publications, were
coded before moving on to the next drug. Additional coders
were trained to double-code portions of the data determined
to be potentially subjective in both the FDA reviews and the
publications (see Box 1). Double-coding was done in a
separate random order and was performed for all papers (n
¼ 126) and for a randomly selected subset of NDA trials (n ¼
55). Disagreements were resolved by consensus. Because
previous research suggests that masking of articles to
reviewers does not inﬂuence ratings, reviewers were not be
blinded to the source or authors of the articles [17–19]. Inter-
coder reliability was very good (simple kappa 0.71 to 1).
We collected data on characteristics of randomized
controlled trials that could inﬂuence bias including random-
ization [20,21], double blinding [21,22], choice of drug
comparator [23–26], peer-review status of the publication
[27], funding source [28,29], and ﬁnancial ties of investigators
[29,30] because these are characteristics that could be
associated with publication (see Box 1 for data coding).
Details on the collection of outcomes and conclusions, as well
as publication status, are described below.
Primary outcome(s) (double-coded). The primary out-
come(s), as identiﬁed in the FDA review of the NDA or the
publication, were recorded for each trial. If a primary
outcome was measured at different times, we used the time
point that was speciﬁed in the NDA as the primary outcome.
If a primary outcome was not explicitly stated, the outcome
used in the power analysis was designated as the primary
outcome. If the power analysis was not provided or an
outcome was not stated, then the outcome stated in the
primary research question was designated as primary. If a
primary outcome was not identiﬁed by any of these methods,
the trial was considered to have no primary outcomes
reported.
For each primary outcome, we recorded: deﬁnition of the
outcome, whether the outcome measured efﬁcacy or safety,
and the statistical signiﬁcance of the outcome. Statistical
signiﬁcance of the outcome was coded as 1) statistically
signiﬁcant in favor of the NDA drug (e.g., p , 0.05, 95% CI
for difference excluding 0, or 95% CI for ratio excluding 1),
2) not statistically signiﬁcant, 3) statistically signiﬁcant in
favor of the comparator or 4) unknown. For trials with only
one primary outcome, the outcome was considered favorable
if it was a superiority outcome that was statistically signiﬁcant
in favor of the NDA drug or in which equivalence was found.
Superiority outcomes that were not statistically signiﬁcant or
that favored the comparator were considered not favorable,
and outcomes for which the signiﬁcance was not reported
were excluded (13 out of 196 outcomes).
For trials with multiple primary outcomes, a composite
ﬁeld was made and was coded on the basis of the statistical
signiﬁcance of each primary outcome in the trial. The
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least one primary outcome was statistically signiﬁcant in
favor of the drug and no primary outcomes were statistically
signiﬁcant in favor of the comparator or (2) not favorable: no
primary outcomes were statistically signiﬁcant in favor of the
NDA drug or at least one primary outcome was statistically
signiﬁcant in favor of the comparator.
Conclusion (double-coded). The conclusion for each trial,
as stated in the FDA review of the NDA or publication, was
recorded as (1) favorable to the test drug, (2) neutral, (3) not
favorable to the test drug, or (4) unknown/not stated.
Publication status. The publication status of each NDA trial
was recorded as (1) individual publication, (2) publication in
press, (3) pooled publication reported separately, (4) pooled
publication not reported separately, (5) abstract, (6) poster,
(7) not published, veriﬁed, or (8) no information found.
For analysis, the coding categories above were dichotom-
ized as ‘‘published’’ or ‘‘not published.’’ A trial was coded as
‘‘published’’ if it was in categories 1, 2, or 3 above; it was
coded as an individual publication if one or more publica-
tions were identiﬁed reporting only the results of that speciﬁc
trial; as in press; or as a pooled publication if multiple trials
were included but the results of the NDA trial were reported
separately. All other trials (categories 4, 5, 6, 7 or 8) were
considered ‘‘not published.’’
In cases of duplicate publications, the reports were
reviewed to identify the more complete publication, and
only this publication was included in the analysis. In many
cases, publications were identiﬁed as post-hoc analyses or
reports of secondary variables. If the identity of the primary
publication was unclear, the authors were contacted and
asked to identify the primary publication.
Statistical Analysis
For our primary outcome of publication, we report the
publication status of NDA trials in terms of the whole
population of trials (the percentage of trials published) as
well as per NDA (the percentage of NDAs with at least one
published trial). We report the frequency of the different
characteristics of each trial as reported in both the FDA
reviews of the NDA and the publication (see Box 1 for list of
characteristics). For characteristics for which there was
sufﬁcient variability, we assessed whether there was an
association with publication.
Associations between individual trial characteristics as
reported in the NDA and publication were ﬁrst analyzed
using univariate logistic regression, with a random effect
included to account for possible similarity of trials from the
same NDA, and odds ratios were estimated. Multivariate
models were then built in a forward stepwise manner until no
remaining candidate predictors had p , 0.05.
For the subset of published trials, we compared the
characteristics of the NDA trials with their corresponding
publication. We tested for systematic changes in the reporting
of each trial characteristic from the individual NDA report to
the published report using McNemar’s test for dichotomous
variables and the paired t-test for numeric variables.
We identiﬁed primary outcomes that were added or deleted
from papers and report the statistical signiﬁcance of these
outcomes. We also report changes in statistical signiﬁcance of
primary outcomes from the NDA to publication.
We report changes in conclusions from the NDA to
publication.
Results
Characteristics of Included Trials from NDAs
Our ﬁnal sample consisted of 164 efﬁcacy trials found in 33
NDAs (see Figure 1). The NDAs were supported by a range of
1–13 trials with a median of four trials. See Table S1 for list of
NDAs and included trials.
Box 1. Coding of Study Design and Publication Characteristics
Study design (single-coded; coded for NDA trials only)
Randomization: Recorded as (1) yes or (2) no/unknown.
Blinding: Recorded as (1) single blind, (2) double blind, (3) triple blind, or
(4) open label (not blinded).
Study design (double-coded; coded for NDA trials and publications)
Intervention groups: Details for each intervention group were recorded,
including: drug name, dose, frequency, route, duration, and whether the
drug was an NDA drug, comparator drug or placebo.
Intention to treat (ITT): Recorded as (1) yes or (2) no/unknown. Each trial
was coded as using ITT analysis if the number of patients for the primary
efficacy analysis equaled the number of patients randomized. If use of
ITT was stated in the methods, but randomized patients were omitted
from the primary efficacy population, then the field was coded as ‘‘ITT
not done, but report states that it was done.’’ We applied the following
definition of ITT: ‘‘All participants should be included regardless of
whether their outcomes were actually collected.’’ [37].
Last observation carried forward (LOCF): Recorded as (1) yes or (2) no/
unknown
Data imputation: Recorded as (1) yes or (2) no/unknown. This included
those trials that used LOCF.
Data reporting: Reporting of raw data (e.g., counts or means with no
statistical manipulation, such as, number of patients with outcome, actual
blood pressure as opposed to change in blood pressure), percent data
(e.g., X% of patients responded), absolute change, relative risk, and number
need to treat (NNT) for the primary outcome(s) of each trial was recorded.
Uncertainty reporting: Reporting of p-values, confidence intervals, and
standard deviation for the primary outcome(s) of each trial was recorded.
Adverse events table: Each trial was assessed for the presence of an
adverse event table. Details of statistically significant adverse events
were also recorded.
Publication characteristics (single-coded; coded for publications only)
Funding: The funding source(s), as disclosed in each paper, were
recorded as (1) industry, (2) government, (3) non-profit, or (4) not
disclosed. The specific funding source(s) were also recorded.
Disclosure of conflicts: Disclosure of conflicts in each paper was recorded
as (1) individual conflicts disclosed (details recorded under each author),
(2) conflicts not disclosed, (3) employees only disclosed, or (4) ‘‘no
conflicts’’ explicitly stated.
Author affiliation with industry: Recorded as (1) yes or (2) no/unknown.
Details of any affiliation with industry (such as employment by industry)
were recorded for each author, as disclosed in the publication.
Peer-review status of journal: Each journal article was classified as peer-
reviewed, not peer-reviewed or unknown status. The editorial office of
each journal was contacted to determine whether the journal was peer
reviewed and, if peer-reviewed, how long a peer review process had
been in place to ensure that earlier publications were included in the
peer review process. Websites were also consulted for those journals for
which the editorial office did not reply.
Impact factor: The impact factor was obtained for each journal for the
year in which each article was published from the Institute for Scientific
Information website [38]. Impact factors that were not found at the ISI
website (articles published before 2000) were found in the UCSF library
microfilms in the Science Citation Index Journal Citation Reports from
the Institute for Scientific Information.
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by publication status. All trials were reported as randomized
except for one, for which randomization was not mentioned.
There were approximately equal proportions of active- and
placebo-controlled trials. Only 14% (23/164) of trials used
intention to treat (ITT) analysis as their primary analysis.
Furthermore, the deﬁnition of ITT that we used (see Box 1)
includes per-protocol analysis (in which participants are
analyzed as treated rather than as randomized). Thus, an even
lower proportion of trials adhered to ITT analysis deﬁned as
all participants included in the arm to which they were
allocated, whether or not they received (or completed) the
intervention given to that arm. Another 53% (74/141) stated
that they conducted ITT analysis, although their primary
analysis did not include all randomized patients. Uncertainty
was most frequently reported as a p value (81%, 132/163),
although 45% (73/163) of trials reported conﬁdence intervals.
The primary outcome composite ﬁeld was favorable to the
test drug in 76% (124/163) of the trials. The conclusion
favored the test drug in 70% (114/164), was neutral in 7% (11/
164), was not favorable to the test drug in 4% (7/164), and was
unknown in 20% (32/164) of trials.
Publication Status
As shown in Table 1, 77% (128/164) trials were published,
which included 100 individual publications, 26 pooled
publications, and two in-press publications. The two trials
that were in press were omitted from all subsequent analyses
comparing NDA trials with publications. Of the 36 trials that
were not published, 15 were incompletely published in either
a pooled publication or an abstract and 12 were veriﬁed as
not published. Information for nine trials could not be found,
even after multiple contacts with the drug companies and
authors of other publications.
The NDAs had a range of one to 13 published trials, with
94% (31/33) of NDAs having at least one trial published, and
52% (17/33) of NDAs having all trials published. There were
two NDAs (dutasteride and perﬂutren), with a total of ﬁve
trials, for which no trials were published (see Table S1).
We did not identify any speciﬁc cases in which sponsors
prohibited investigators from publishing. However, some
investigators did comment that they had been eager to publish
their ﬁndings. As one investigator stated, ‘‘The data are in my
opinionvery worthwhile. Efforts were made a number of times
to work on publishing the data, but it was never possible to
ﬁnd a time when both the PI and the company simultaneously
had time available to commit.’’ Another commented, ‘‘Un-
fortunately I do not think this complete study has ever been
published. It is clearly important that thisshould be published.
I have been and continue to be in contact with [Company] to
see how this can be published.’’
Predictors of Publication
Table 2 shows the results of univariate logistic regression
analyses, which found that trials that were reported in the
NDA as having active controls or with favorable primary
outcomes were signiﬁcantly more likely to be published. In a
multivariate model, both active control and favorable
primary outcome remained signiﬁcant. No other variable
had p , 0.05 when added to the model with those two
predictors. Although favorable conclusion had a sizeable
estimated odds ratio in the univariate model, this disap-
peared when controlling for active controls and favorable
primary outcomes (OR ¼ 0.99, 95% CI 0.15 to 6.4, p ¼ 0.99).
Discrepancies between Data Analysis and Reporting in the
NDA and Published Trials
As shown in Table 3, there were statistically signiﬁcant
changes in the reporting of types of data, p values, conﬁdence
intervals, and adverse event tables in the publications as
compared with the NDAs.
Discrepancies in Primary Outcome Reporting
As shown in Table 4, trials had a total of 179 primary
outcomes reported in the NDAs. Forty-one primary outcomes
from the NDAs were omitted from the papers. Papers
included 155 outcomes that were also in the NDAs (87%,
155/179), plus 15 additional outcomes that favored the test
drug, and two other neutral or unknown additional out-
comes. Thus, the papers included more outcomes favoring
the test drug than did the NDAs.
Excluding outcomes with unknown signiﬁcance, there were
43 outcomes in the NDAs that did not favor the test drug (35
not statistically signiﬁcant, eight favored the comparator). Of
these outcomes, 20 (47%) were not included in the papers. In
addition, the statistical signiﬁcance of ﬁve of the remaining
23 outcomes (22%) changed between the NDA and the paper,
with four changing to favor the test drug in the paper (p ¼
0.38). The changes in outcomes occurred in a total of 36 trials
found in 19 different NDAs.
Discrepancies in Conclusions
As shown in Table 5, when excluding unknown conclusions,
99 conclusions were provided in both NDAs and papers.
There were ten conclusions in the NDAs that did not favor
the test drug (six neutral and four favoring the comparator).
Excluding unknowns, nine conclusions (9%) changed from
the FDA review of the NDA to the paper, and all nine did so
to favor the test drug (100%, 95% CI 72% to 100%, p ¼
Figure 1: Flow Chart for Selection of New Drug Applications and
Included Trials
doi:10.1371/journal.pmed.0050217.g001
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Type of Analysis Predictor OR (95% CI) p-Value
Univariate Sample size   median (median ¼ 405
a) 0.78 (0.31–2.0) 0.60
Number of sites   median (median ¼ 32) 0.35 (0.10–1.18) 0.088
Active control (versus placebo only) 2.84 (1.08–7.51) 0.036
Favorable primary outcome composite 4.32 (1.18–15.76) 0.028
Favorable conclusion 2.47 (0.66–9.32) 0.17
Bivariate Active control (versus placebo only) 3.37 (1.02–11.22) 0.047
Favorable primary outcome composite 4.77 (1.33–17.06) 0.018
aDiffers from Table 1 because of exclusion of two papers in press.
doi:10.1371/journal.pmed.0050217.t002
Table 1. Characteristics of Included NDA Trials by Publication Status (n ¼ 164)
Characteristic Category Subcategory All NDA Trials
(n ¼ 164)
a
NDA Trials, Published
or In Press (n ¼ 128)
b
NDA Trials, Not
Published (n ¼ 36)
Trial size Sample size randomized Median (min–max) 386 (15–2421) 392 (15–2421) 345.5 (32–1522)
Number of sites Median (min–max) 34.5 (1–205) 35.5 (1–199) 24.5 (1–205)
Trial methodology Randomized 99% (163/164) 99% (127/128) 100% (36/36)
Blinded 95% (155/164) 94% (120/128) 97% (35/36)
Number of primary outcomes 0 0.6% (1/164) 0.8% (1/128) 0
1 74% (122/164) 74% (95/128) 75% (27/36)
2 14% (23/164) 15% (19/128) 11% (4/36)
3 or more 11% (18/164) 10% (13/128) 14% (5/36)
Number of intervention groups 2 40% (66/164) 41% (52/128) 39% (14/36)
3 24% (39/164) 24% (31/128) 22% (8/36)
4 16% (26/164) 16% (21/128) 14% (5/36)
5 or more 20% (33/164) 19% (24/128) 25% (9/36)
Control group Active control 51% (84/164) 56% (72/128) 33% (12/36)
Data analysis and reporting Intention to treat used 14% (23/164) 15% (19/128) 11% (4/36)
Intention to treat claimed
c 53% (74/141) 53% (58/109) 44% (16/36)
LOCF
d 35% (57/164) 32% (41/128) 44% (16/36)
Data imputation
e 41% (67/164) 39% (50/128) 47% (17/36)
Data reporting
f Raw (counts, means) 71% (115/163) 76% (96/127) 53% (19/36)
Percent 45% (74/163) 49% (62/127) 33% (12/36)
Absolute change 53% (86/163) 48% (61/127) 69% (25/36)
Results reporting
f Relative risk 4% (7/163) 4% (5/127) 6% (2/36)
NNT
g 00 0
Uncertainty reporting
f,h p-Value 81% (132/163) 80% (101/127) 86% (31/36)
Confidence interval 45% (73/163) 47% (60/127) 36% (13/36)
Standard deviation 36% (59/163) 41% (52/127) 19% (7/36)
Results and conclusions Conclusion Favorable 70% (114/164) 70% (90/128) 67% (24/36)
Neutral 7% (11/164) 6% (7/128) 11% (4/36)
Not favorable 4% (7/164) 3% (4/128) 8% (3/36)
Unknown 20% (32/164) 21% (27/128) 14% (5/36)
Primary outcome composite
f Favorable 76% (124/163) 80% (102/127) 61% (22/36)
Not favorable 18% (29/163) 15% (19/127) 28% (10/36)
Unknown 6% (10/163) 5% (6/127) 11% (4/36)
Adverse event table 40% (66/164) 42% (54/128) 33% (12/36)
Equivalence outcome
f 14% (23/163) 16% (20/127) 8% (3/36)
aPercentages may not add up to 100 as percentages of 0.5 were rounded up.
bTwo were reported as ‘‘in press.’’
cAnalyzed for only those trials in which intention to treat (ITT) was not used, identifying those trials that claimed use of ITT but did not actually use ITT as defined in our methods (see Box 1).
dLOCF ¼ Last Observation Carried Forward.
eIncludes those trials that used LOCF.
fThere was one trial for which no primary outcome was reported. Thus, this trial had no numerical reporting of data and the denominator is 163 for the categories of data, results and
uncertainty reporting, primary outcome composite, and equivalence outcome.
gNNT ¼ number needed to treat.
hThe choices for uncertainty reporting were not mutually exclusive. Trials often reported uncertainty in more than one way (for example, many gave the confidence interval and the p
value for each outcome). Therefore the sum of these fields is greater than 164.
doi:10.1371/journal.pmed.0050217.t001
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Reporting Bias in Drug Trials0.0039). Including the unknowns, 35 of 36 that changed did so
to favor the test drug (p , 0.0001).
The changes in statistical signiﬁcance of outcomes and
conclusions were too few to permit a meaningful investiga-
tion of predictors.
Characteristics of Publications
Peer review was conﬁrmed for 93% (117/126) of publica-
tions, was conﬁrmed as not done for 3% (4/126) of
publications, and was unknown for the other ﬁve. Most
publications (n ¼ 102) were in journals that had an impact
factor, with a median of 4.14 (range 0.85–34.83). Reporting of
conﬂicts of the individual authors varied, with 57% (72/126)
reporting only whether authors were employees of companies,
and 7% (9/126) not reporting conﬂicts at all. Only 4% (5/126)
speciﬁcally stated that the authors did not have any conﬂicts.
At least one author was afﬁliated with industry in 80% (101/
126), and all authors were reported as afﬁliated with industry
in 15% (19/126) of publications. The majority of publications
(77%, 97/126) reported funding, at least in part, by industry.
Discussion
Publication bias can occur in several ways, including not
publishing data at all, selectively reporting data, or framing
data. We found evidence of both lack of publication and
selective reporting of data. Seventy-eight percent of the trials
submitted to the FDA were published, and trials with active
controls or statistically signiﬁcant outcomes favoring the test
drug were more likely to be published. In a multivariate
model, trials with favorable primary outcomes (OR¼4.7, 95%
CI 1.33 to 17.1, p¼0.018) and active controls (OR¼3.4, 95%
CI 1.02 to 11.2, p¼0.047) were more likely to be published. In
addition, reporting sometimes differed between trials as they
were described in FDA reviews and their corresponding
publications. These changes included the addition or deletion
of outcomes, changes in statistical signiﬁcance of reported
outcomes, and changes in overall trial conclusions. Papers
included 155 outcomes that were also in the NDAs, 15
additional outcomes that favored the test drug, and two other
neutral or unknown additional outcomes. Excluding out-
comes with unknown signiﬁcance, there were 43 outcomes in
the NDAs that did not favor the NDA drug. Of these, 20 (47%)
were not included in the papers. The statistical signiﬁcance of
ﬁve of the remaining 23 outcomes (22%) changed between
the NDA and the paper, with four changing to favor the test
drug in the paper (p ¼ 0.38). Excluding unknowns, 99
conclusions were provided in both NDAs and papers, nine
conclusions (9%) changed from the FDA review of the NDA
Table 4. Numbers of Primary Outcomes with Concordance or Changes in Reporting from NDA to Publication
Statistical Significance
in Paper
Statistical Significance in NDA Total for
Paper Favor Test Drug Not Statistically Significant Favor Comparator Unknown Not in NDA
Favor test drug 108 3 1 5 15 132
Not statistically significant 0 17 0 0 1 18
Favor comparator 0 1 1 1 0 3
Unknown 0 0 0 1 1 2
Not in paper 15 14 6 6 0 41
Total for NDA 123 35 8 13 17 196
doi:10.1371/journal.pmed.0050217.t004
Table 3. Numbers of Trials with Discrepancies Concerning Data Analysis and Reporting Between the NDAs and the Published Trials
Data Analysis and
Reporting Category
Subcategory Reported in NDA,
Not Paper
a
Reported in Paper,
Not NDA
a
p-Value
b
Intention to treat used 8 10 0.81
Intention to treat claimed 16 13 0.71
LOCF 10 11 1.0
Data imputation 15 16 1.0
Data reporting Raw data (counts or means) 35 2 ,0.0001
Percents 12 1 0.0034
Absolute change 9 1 0.021
Results reporting Relative risk 4 8 0.39
NNT 0 0 —
Uncertainty reporting p-Value 3 15 0.0075
Confidence interval 23 11 0.058
Standard deviation 13 14 1.0
Adverse event table 19 45 0.0016
Equivalence outcome 4 3 1.0
aTotal number of NDA-publication pairs is 126; tallies not shown are concordant.
bExact two-sided McNemar test.
doi:10.1371/journal.pmed.0050217.t003
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Reporting Bias in Drug Trialsto the paper, and all nine did so to favor the test drug (100%,
95% CI 72% to 100%, p ¼ 0.0039). All of these changes in
reporting led to more favorable presentations of the NDA
drug in the published articles.
Our ﬁndings extend those of others by demonstrating that
reporting bias occurs across a variety of drug categories and
that statistical signiﬁcance of reported primary outcomes
sometimes changes to give a more favorable presentation in
the publications [10–12]. These changes occur primarily in
peer-reviewed, moderate impact factor journals that disclose
funding sources and other ﬁnancial ties. Thus, publication of
trial data in peer-reviewed publications appears to be
inadequate, supporting the need for reporting of full
protocols and ﬁndings in a trial registry [31–34]. There have
been several advances in trial registration, including The
World Health Organization International Clinical Trials
Registry Platform, a US register (http://www.clinicaltrials.
gov), and the International Committee of Journal Editors
requirement for pre-registration of all trials published in
participating journals from late 2005, and the FDA Amend-
ments Act requirements for study results posting. Our
ﬁndings suggest that these registries should contain, at a
minimum, full reporting of results for all primary outcomes
that are reported for trials submitted for regulatory approval.
Responses from investigators to our inquiries about
unpublished studies suggest that studies were not published
because they were not submitted to journals. Several other
studies, based on self-reports from authors with unpublished
studies, suggest that authors’ decisions not to submit manu-
scripts account for the majority of unpublished studies
[2,7,8,35]. A prospective cohort study of 1107 manuscripts
submitted to three major medical journals found that having
statistically signiﬁcant results did not improve the chance of a
study being published, although studies of higher methodo-
logical rigor were more likely to be published [36]. In our
opinion, investigators have an ethical obligation to submit
the results of their research for publication.
Our study has several limitations. We were unable to
determine why results were changed from the FDA review of
the trial in the NDA to publication. Possible explanations for
changes in the primary outcome(s) include: there was a
problem with the measurement of the primary outcome as
identiﬁed by the sponsor or the FDA; the primary outcome as
submitted to the FDA did not have a favorable result; or the
primary outcome was criticized by the FDA. Changes in the
reporting of the signiﬁcance of primary outcome(s) may have
been due to either changes in analysis initiated by the
sponsor in order to improve the results or changes in analysis
due to criticism by the FDA of the initial analysis used. We
could not investigate predictors of change to more favorable
results because almost all of the results started out as
favorable, therefore leaving only a small subset of results
that could change to more favorable reporting in the
publication. Another limitation was the quality of our data
sources from the FDA. Although clinical trial data submitted
to the FDA are publicly available, they are not in a format
that is easily accessible, and the documents are often
incomplete. Trials that are included in the efﬁcacy or safety
analysis are not clearly indicated. They could, for example, be
listed in a table. In addition, the data are available only in the
FDA review, and not as originally submitted by the sponsor.
Thus, the primary outcomes as identiﬁed in the FDA review
could differ from those listed in the original trial protocol.
Lastly, it is possible that sponsors may not submit all their
data to the FDA.
The goal of this study was to determine whether informa-
tion that is available to the FDA is readily accessible to
clinicians, and whether it is presented in the same way. As we
hypothesized, not all data submitted to the FDA in support of
a new drug approval were published, and there were
discrepancies between original trial data submitted to the
FDA and data found in published trials. Thus, the informa-
tion that is readily available in the scientiﬁc literature to
health care professionals is incomplete and potentially
biased.
Supporting Information
Table S1. List of NDAs
Found at doi:10.1371/journal.pmed.0050217.st001 (78 KB DOC).
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Background. All health-care professionals want their patients to have
the best available clinical care—but how can they identify the optimum
drug or intervention? In the past, clinicians used their own experience or
advice from colleagues to make treatment decisions. Nowadays, they
rely on evidence-based medicine—the systematic review and appraisal
of clinical research findings. So, for example, before a new drug is
approved for the treatment of a specific disease in the United States and
becomes available for doctors to prescribe, the drug’s sponsors (usually a
pharmaceutical company) must submit a ‘‘New Drug Application’’ (NDA)
to the US Food and Drug Administration (FDA). The NDA tells the story of
the drug’s development from laboratory and animal studies through to
clinical trials, including ‘‘efficacy’’ trials in which the efficacy and safety of
the new drug and of a standard drug for the disease are compared by
giving groups of patients the different drugs and measuring several key
(primary) ‘‘outcomes.’’ FDA reviewers use this evidence to decide
whether to approve a drug.
Why Was This Study Done? Although the information in NDAs is
publicly available, clinicians and patients usually learn about new drugs
from articles published in medical journals after drug approval.
Unfortunately, drug sponsors sometimes publish the results only of
the trials in which their drug performed well and in which statistical
analyses indicate that the drug’s improved performance was a real effect
rather than a lucky coincidence. Trials in which a drug did not show a
‘‘statistically significant benefit’’ or where the drug was found to have
unwanted side effects often remain unpublished. This ‘‘publication bias’’
means that the scientific literature can contain an inaccurate picture of a
drug’s efficacy and safety relative to other therapies. This may lead to
clinicians preferentially prescribing newer, more expensive drugs that are
not necessarily better than older drugs. In this study, the researchers test
the hypothesis that not all the trial results in NDAs are published in
medical journals. They also investigate whether there are any discrep-
ancies between the trial data included in NDAs and in published articles.
What Did the Researchers Do and Find? The researchers identified all
the efficacy trials included in NDAs for totally new drugs that were
approved by the FDA in 2001 and 2002 and searched the scientific
literature for publications between July 2006 and June 2007 relating to
these trials. Only three-quarters of the efficacy trials in the NDAs were
published; trials with favorable outcomes were nearly five times as likely
to be published as those without favorable outcomes. Although 155
primary outcomes were in both the papers and the NDAs, 41 outcomes
were only in the NDAs. Conversely, 17 outcomes were only in the papers;
15 of these favored the test drug. Of the 43 primary outcomes reported
in the NDAs that showed no statistically significant benefit for the test
drug, only half were included in the papers; for five of the reported
primary outcomes, the statistical significance differed between the NDA
and the paper and generally favored the test drug in the papers. Finally,
nine out of 99 conclusions differed between the NDAs and the papers;
each time, the published conclusion favored the test drug.
What Do These Findings Mean? These findings indicate that the results
of many trials of new drugs are not published 5 years after FDA approval
of the drug. Furthermore, unexplained discrepancies between the data
and conclusions in NDAs and in medical journals are common and tend
to paint a more favorable picture of the new drug in the scientific
literature than in the NDAs. Overall, these findings suggest that the
information on the efficacy of new drugs that is readily available to
clinicians and patients through the published scientific literature is
incomplete and potentially biased. The recent introduction in the US and
elsewhere of mandatory registration of all clinical trials before they start
and of mandatory publication in trial registers of the full results of all the
predefined primary outcomes should reduce publication bias over the
next few years and should allow clinicians and patients to make fully
informed treatment decisions.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050217.
  This study is further discussed in a PLoS Medicine Perspective by
An-Wen Chan
  PLoS Medicine recently published a related article by Ida Sim and
colleagues: Lee K, Bacchetti P, Sim I (2008) Publication of clinical trials
supporting successful new drug applications: A literature analysis.
PLoS Med 5: e191. doi:10.1371/journal.pmed.0050191
  The Food and Drug Administration provides information about drug
approval in the US for consumers and for health-care professionals;
detailed information about the process by which drugs are approved
is on the Web site of the FDA Center for Drug Evaluation and Research
(in English and Spanish)
  NDAs for approved drugs can also be found on this Web site
  The ClinicalTrials.gov Web site provides information about the US
National Institutes of Health clinical trial registry, background
information about clinical trials, and a fact sheet detailing the
requirements of the FDA Amendments Act 2007 for trial registration
  The World Health Organization’s International Clinical Trials Registry
Platform is working toward setting international norms and standards
for the reporting of clinical trials (in several languages)
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